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Edited by Laszlo Nagy and Peter TontonozAbstract Retinoids, naturally-occurring vitamin A derivatives,
regulate metabolism by activating speciﬁc nuclear receptors,
including the retinoic acid receptor (RAR) and the retinoid X
receptor (RXR). RXR, an obligate heterodimeric partner for
other nuclear receptors, including peroxisome proliferator-acti-
vated receptors (PPARs), helps coordinate energy balance. Re-
cently, many groups have identiﬁed new connections between
retinoid metabolism and PPAR responses. We found that reti-
naldehyde (Rald), a molecule that can yield RA through the ac-
tion of retinaldehyde dehydrogenases (Raldh), is present in fat
in vivo and can inhibit PPARc-induced adipogenesis. In vitro,
Rald inhibits RXR and PPARc activation. Raldh1-deﬁcient mice
have increased Rald levels in fat, higher metabolic rates and body
temperatures, and are protected against diet-induced obesity and
insulin resistance. Interestingly, one speciﬁc asymmetric b-caro-
tene cleavage product, apo-14 0-carotenal, can also inhibit
PPARc and PPARa responses. These data highlight how path-
ways of b-carotene metabolism and speciﬁc retinoid metabolites
may have direct distinct metabolic eﬀects.
Crown Copyright  2007 Published by Elsevier B.V. on behalf of
the Federation of European Biochemical Societies. All rights
reserved.
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Obesity; Apocarotenal1. Complex action of retinoids – a family of biologically active
mediators with poorly understood actions
Retinoids are a large group of naturally-occurring vitamin A
derivatives that regulate key cellular processes [1]. Indeed, spe-
ciﬁc retinoids have been reported to be involved in cell diﬀeren-
tiation, cell cycle control, cell growth, and cellular responses to
cell injury. At the same time, retinoids are also strongly impli-
cated in various ways in the pathogenesis of obesity, diabetes,
and cardiovascular disease. Retinoids are also in clinical use
as pharmaceutical agents employed in treating speciﬁc patho-
logic conditions including leukemia and skin disorders [2,3].
Given this broad, fairly evolved portfolio – involvement in fun-
damental biologic processes, implication in pathogenesis, and
use in therapeutic applications – it is surprising how much re-*Corresponding author. Fax: +1 617 525 4366.
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doi:10.1016/j.febslet.2007.11.081mains unknown about speciﬁc retinoid metabolites, their gen-
eration, their involvement in distinct biologic responses, or
how discrete pathways of retinoid metabolism inﬂuence disease
states or might be harnessed for clinical beneﬁt. Here we will re-
view basic mechanisms through which retinoids exert their ef-
fects and discuss new insights into how retinoid metabolism
and handling may direct key metabolic pathways.2. Mechanisms of retinoid action
Retinoids have been reported to exert versatile cellular ef-
fects including functional eﬀects biomembranes [4], participa-
tion in post-transcriptional protein modiﬁcation by
retinoylation [5], and phosphorylation of speciﬁc proteins [6].
A fundamental mechanism for retinoid action is through tran-
scriptional regulation [7]. Retinoids regulate gene expression
by acting in a hormone-like fashion, binding to the ligand
binding domain of speciﬁc nuclear hormone receptors, and
thus activating them [7]. In the case of the retinoic acid recep-
tor (RAR) [7], the highest binding aﬃnity was seen with reti-
noic acid (RA) in the all-trans conformation [8]. Two RA
isomers have been identiﬁed in vivo: the most abundant is
all-trans-RA, while 13-cis-RA is detected at signiﬁcantly lower
concentrations in both mice and humans [9,10]. The 9-cis RA
isomer has never been identiﬁed in vivo [11], despite newer
methods able to quantitate fentomolar levels of this isomer
[9]. All RA isomers bind and activate RAR in vitro, albeit
all-trans and 9-cis RA isomers bind more eﬃcaciously than
13-cis isomer [8]. The in vivo activation of all RAR isoforms
(RARa, RARb, RARc) is mediated by the all-trans RA iso-
mer, as reported in numerous genetic and pharmacological
studies [1,9,10].
The endogenous role of all-trans RA has been demonstrated
in mice lacking retinaldehyde dehydrogenase 2 (Raldh2), a key
enzyme for RA production during embryogenesis (Fig. 1). The
early growth arrest evident in Raldh2-deﬁcient (Raldh2/) em-
bryos is rescued by administration of all-transRA or a synthetic
RAR ligand [11]. In contrast 9-cis RA isomers could not com-
pensate for deﬁcient RA synthesis in these mice [11]. Thus, only
the all-trans RA isomer functions as an endogenous ligand for
RAR, despite other RA isomers in pharmacologic studies exert-
ing distinct eﬀects in multiple pathways. Even this one example
highlights the importance of vitamin A (retinol) metabolism in
generating speciﬁc metabolites, and thus unique transcriptional
responses via activation of speciﬁc nuclear receptors. Otherlf of the Federation of European Biochemical Societies. All rights reserved.
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Fig. 1. Vitamin A and b-carotene metabolism generates Rald and RA.
The major steps in the metabolism of vitamin A (retinol), retinyl esters,
and b-carotene central cleavage leading to the generation of retinalde-
hyde (Rald). Asymmetric b-carotene cleavage produces apocarotenals
including b-apo-140 carotenal (apo14, see Fig. 3). Retinaldehyde (Rald)
is generated from retinol by a family of alcohol dehydrogenases (Adh1,
3, 4). Short-chain alcohol dehydrogenases catalyze reversible reactions
involving retinol oxidation to Rald and Ralds subsequent reduction to
retinol. Two Rald molecules can be produced as a result of symmetric
b-carotene cleavage. Retinaldehyde dehydrogenases (Raldh1–4) are a
family of enzymes that produce retinoic acid (RA) from Rald.
Retinoids function as ligands for various nuclear receptors (NRs) that
can promote (+) or repress () adipogenesis. All RA isomers are
natural ligands for RAR, while the 9-cis isomer can activate RXR
in vitro. RXR, as an obligate heterodimeric nuclear receptor (NR)
partner, can aﬀect numerous other NRs involved in adipogenesis,
including the liver X receptor (LXR), the vitamin D receptor (VDR),
and the thyroid hormone receptor (TR) to name a few. Recent work has
shed new light on how retinoids are involved in PPAR responses,
including data shown here for how Rald and apo14 can inhibit RXR
and PPAR responses in vitro and in vivo in distinct ways.
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can be hydrolyzed to vitaminA (retinol), with subsequent oxida-
tion of retinol to retinaldehyde (Rald), followed by oxidation of
Rald to yield RA [1] (Fig. 1). These pathways deﬁne the impor-
tance of vitamin A as a parent compound from which various
metabolites are generated. Vitamin A is stored in a transcrip-
tionally inactive esteriﬁed form predominantly in liver and adi-
pose tissue [2,8]. In addition to the nature of the speciﬁc retinoid
ligand that is formed, another key determinant of biologic re-
sponses via vitamin A metabolism is the biology of the nuclear
receptors targeted by these molecules.3. Nuclear receptors as mediators of retinoid responses
RAR belongs to a large family of steroid hormone nuclear
receptors sharing a similar pattern of regulation [12]. Upon
activation by a cognate ligand, nuclear receptors attract small
molecules generally known as co-activators while releasing
co-repressors, ultimately forming an obligate heterodimeric
complex with another retinoid receptor, the retinoid X receptor(RXR) [13]. Although RAR controls many metabolic genes,
many others are not RAR targets [14]. RXR can also regulate
transcription in a homodimeric complex as well. Through its
role as a required heterodimeric partner, RXR can control
the function of many other nuclear receptors, thus integrating
a unique transcriptional network dependent on retinoid metab-
olism and RXR responses [14]. RXR forms heterodimers with
peroxisome proliferator-activated receptors (PPAR), the vita-
min D receptor, the liver X receptor, farnesoid X receptor
(FXR), and other key transcriptional sensors of nutrients and
metabolites that help maintain homeostasis in metabolism im-
mune responses as well as other pathways [13].
RXR is activated by its own ligand, the identity of which has
remained controversial. An early hypothesis suggested that
RXR could be activated through the generation of 9-cis RA,
a molecule that demonstrated high-aﬃnity RXR binding
in vitro [15]. In the absence of its ligand, RXR can form tetra-
mers that regulate distinct response elements [16,17]. In the
presence of 9-cis RA, the RXR tetramer dissociates into
RXR homodimers with unique transcriptional eﬀects. Other li-
gand-activated nuclear receptors can recruit RXR for heterodi-
mer formation [18]. Although 9-cis RA remains perhaps the
most studied speciﬁc RXR ligand [19], the evidence establishing
9-cisRA as the physiologic endogenous agonist for RXR is less
clear [9,11]. As noted, the evidence for this compound in vivo
has been lacking despite sensitive analytical techniques [9,11].
Other studies suggest that biologic RXR responses can occur
in the absence of 9-cisRA [11]. Interestingly, activation of hete-
rodimeric partners of RXR, such as PPARs, can be accompa-
nied by changes in RA production. For example, treatment
of mice with the PPARa synthetic ligand fenoﬁbrate depleted
the hepatic vitamin A content by 50% as compared to mice
on regular chow [20]. Whether an unknown endogenous reti-
noid is produced from vitamin A in these reactions and can
activate RXR, thus supporting heterodimerization with PPAR
deserves further examination. Recent work establishes that the
PPARc agonist rosiglitazone can induce RA-generating en-
zymes retinaldehyde dehydrogenase (Raldh) 1 and 2 and subse-
quent RAR activation in dendritic cells [21]. Since PPARs are
well-established regulators of metabolic pathways in their
own right [22], these data highlight the potential impact reti-
noids might have through eﬀects on PPAR responses. The con-
nections between retinoid metabolism, PPARs and function
responses have been relatively poorly understood.
PPARs are a subfamily of nuclear receptors activated by var-
ious lipids andother biologically-activemolecules [23,24]. Long-
chain fatty acids have been proposed as natural PPAR ligands,
and indeed, speciﬁc endogenous pathways of lipid metabolism
can activate distinct PPAR responses if not generate PPAR ago-
nists [25–27]. All three PPAR isomers – PPARa, PPARb/d, and
PPARc – are involved in gene expression in multiple aspects of
fatty acidmetabolism [28]. PPARa regulates triglyceride synthe-
sis, various aspects of lipoprotein metabolism and transport as
well as both peroxisomal and adaptive mitochondrial b-oxida-
tion of fatty acids [22]. PPARb/d is a key regulator of fatty oxi-
dation in muscle and fat [29]. PPARc plays a critical role in fat,
including fatty acid storage in adipocytes and adipogenesis itself
[30]. PPAR mechanisms have also been linked to the regulation
of glucosemetabolism and control of inﬂammation [29,31]. Syn-
thetic PPAR agonists are in clinical use as therapeutics for treat-
ing type 2 diabetes (thiazolidinediones, PPARc) and
dyslipidemia (ﬁbrates, PPARa) [32]. Possible adverse eﬀects of
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nothing that the retinoid or RXR role in mediating the clinical
eﬀects of PPAR agonists remains poorly understood. Recent
data continue to reveal speciﬁc and somewhat unexpected con-
nections between PPARs and RXR responses.4. Retinoids in the integration of RXR and PPAR responses
As the data for RXR and PPARs as central regulators
jointly controlling multiple key responses emerged, proposed
models kept the biology of retinoids and fatty acids largely
separate. More recent studies have forced this separation to
be reappraised, with new insight into crosstalk between RXR
and PPAR signals. One example of this trend was already
mentioned – the evidence that PPARc could inﬂuence re-
sponses in dendritic cells via Raldh2 [21]. Recently, Noy and
colleagues reported all-trans RA could also function as a spe-
ciﬁc ligand for PPARb/d [35]. Moreover, RA partition between
RXR and PPARb/d depended on cellular RA binding protein
II or keratinocyte fatty acid binding protein, with these intra-
cellular transport proteins delivering RA selectively to either
RAR or PPARb/d, respectively [36]. This channeling of RA
to RAR versus PPARb/d in diﬀerent types of tissues may have
various implications, for example inhibiting or activating pro-
liferation of carcinogenic cells that aﬀects growth of malignant
tumors [36].
Emerging evidence has also suggested that the major vitamin
A metabolite, retinaldehyde (Rald), which had been previously
understood as mainly a unique precursor for RA, could also
function as a speciﬁc transcriptional regulator in its own right
[37]. Rald can exist in various forms, a consequence, at least in
part, of its susceptibility to isomerization and oxidation [38].
These speciﬁc properties of Rald are utilized in eye, where
11-cis-Rald plays an essential role in night vision by complex-
ing with rhodopsin [1,38]. Ralds role in vision depends on
Ralds speciﬁc physical–chemical properties and is independent
in its conversion to RA. Outside the eye, Ralds function has
remained essentially unknown [39]. The fact that Rald produc-
tion from retinol is catalyzed by speciﬁc set of regulated en-
zymes [1,40] suggests a more important role for Rald in
dictating cellular responses. Rald can be generated by alcohol
dehydrogenases (Adh), short-chain dehydrogenases (Sdh or
Rdh), or central cleavage of b-carotene by b-carotene monoox-
ygenase (Bcm, Fig. 1) [1,40,41]. Sdh also catalyzes a reverse
reaction: Rald reduction to retinol [20]. To a large part, Rald
levels depend on its subsequent catabolism by Raldh to RA
[40,42]. The diﬀerences in phenotypes among mice lacking dif-
ferent Adh and Raldh enzymes, and their respective isoforms,
reﬂect speciﬁc functions of these proteins [43]. Moreover, the
expression patterns of Rald-generating and Rald catabolizing
enzymes do not overlap in diﬀerent tissues, further suggesting
that Rald could play a speciﬁc metabolic role in its own right
outside of the eye [40].
Recently, we demonstrated that the enzymes that control
both Rald formation and catabolism are present in fat and dif-
ferentially regulated during adipogenesis [37]. Both the induc-
tion of adipogenesis in vitro and the increased obesity evident
in ob/ob mice in vivo were accompanied by an increased ratio
of Raldh to Adh enzyme expression, changes expected to de-
crease Rald levels. Consistent with this, we found diet-induced
obesity in mice was associated with decreased Rald concentra-tions in adipose tissue [37]. Further examination of the eﬀects
of Rald on transcriptional activity revealed Ralds weak bind-
ing to both PPARc and RXR ligand binding domains and
inhibition of the activation of each of these nuclear receptors
in response to their cognate ligands. Correspondingly, in sev-
eral well established model systems, PPARc target gene
expression was reduced by Rald at low concentration ranges
(30–300 nM), corresponding to Rald levels present in Rald
fat in vivo [37]. In keeping with Ralds eﬀects on both RXR
and PPARc activation in vitro, similar Rald concentrations
as those present in vivo inhibited adipogenesis, even in the
presence of a PPARc agonist. Interestingly, the eﬀects of Rald
were both RXR-dependent and independent. For example,
Rald-mediated repression of adiponectin did not occur after
RXR silencing while triglyceride accumulation during adipo-
genesis persisted even during RXR silencing [37].
This evidence linking Rald with repression of adipogenesis re-
quired further exploration in vivo. Raldh1-deﬁcient (Raldh1/)
micewere already established as amodel of increasedRald levels
[42], although these mice had no obvious metabolic phenotype
[42]. Given the in vitro data, we hypothesized that endogenous
Rald would regulate transcriptional responses in adipose tissue,
modulating adipogenesis and fat formation. Given the role of
the RXR–PPAR complex in energy balance, it seemed plausible
to test this idea under caloric stimulation, as seen with high fat
diet. In this setting, Raldh1-deﬁciency and its associated impair-
ment ofRald catabolism increasedRald levels in fat some 200%.
Consistent with the inhibition of adipogenesis seen after Rald
stimulation in vitro, endogenous increased Rald concentrations
in Raldh1/mice protected these mice from diet-induced obes-
ity and its associated insulin resistance [37]. (Fig. 2). Of note,
Raldh1/ mice remained insulin sensitive in spite of reduced
levels of adiponectin, a major adipokine implicated in the insu-
lin-sensitizing eﬀects of thiazolidinediones [37].
Many potential inputs could contribute to the observed lean,
insulin sensitive phenotype of these mice. One possibility would
be a change in circulating adipokines, for example RBP4, a pro-
tein reported to be altered in insulin resistance states in both
mice and humans [44,45]. Interestingly, Rald binds directly to
RBP4 [37], raising the possibility that Rald may be involved in
the phenotypes seen in association with altered RBP4 levels
[44,45].Another potential input into the phenotype of thesemice
are the systemic shifts in retinoid metabolism deriving from
Raldh1 deﬁciency, with increasedRald levels occurring at the ex-
pense of RA production [42]. Imbalance in these retinoids could
inﬂuence bothRXR-dependent and independent pathways. The
white fat of high fat fed Raldh1/ mice was characterized by
markedly smaller adipocytes than wild-type (WT) mice, a
change reported in other mouse models to correlate with in-
creased insulin sensitivity [37]. The changes in adipocyte size
seen in Raldh1/ mice corresponded directly with Rald levels
seen in adipocytes. It remains to be deﬁned if these Rald-associ-
ated smaller adipocytes in vivo resulted from impaired PPARc
signaling and decreased adipocyte diﬀerentiation or some other
eﬀect. In vitro, preadipocytes isolated from Raldh1/ mice
demonstrated impaired diﬀerentiation and decreased PPARc
target gene expression as compared to similarly diﬀerentiated
cells fromWTmice, thus suggesting possible adipocyte autono-
mous eﬀects [37]. Of note, these changes in adipogenesis in
Raldh1/ adipocytes were rescued by highmicromolar concen-
trations of the PPARc agonist rosiglitazone [37], further sup-
porting Rald-mediated PPARc inhibition. Interestingly, prior
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Fig. 2. Raldh1 deﬁciency protects against diet-induced obesity and insulin resistance by increasing metabolic rates. (A) Age- and sex-matched
Raldh1/ mice (n = 9) and wild-type (WT, n = 10) mice received a high-fat diet (45 kcal%) for 180 days before undergoing metabolic studies. Two
representative X-ray images of each genotype obtained of randomly selected females fromWT andRaldh1/ groups are shown and demonstrate body
mass diﬀerences evident after 120 days of high-fat feeding. There was no signiﬁcant diﬀerence in the total calories consumed and water intake between
Raldh1/ and WT mice. (B) Raldh1/ mice (ﬁlled circles) weighed signiﬁcantly less than WT (open circles) mice at 180 days (*P < 0.001, Wilcoxon
rank test), diﬀerences that were also evident throughout the study (data not shown). Signiﬁcant diﬀerences in adiposity between WT and Raldh1/
mice were evident in fat pads (subcutaneous and omental) as well as liver (data not shown, P < 0.001, Mann–Whitney test). (C) Metabolic cage studies
were performed on WT (n = 5) and Raldh1/ females (n = 4, black bars, d) on similar high fat diet (45 kcal%) for 180 days. Metabolic rates
(means ± S.D.) were measured over 24 h in WT mice (open circles, dashed line) and Raldh1/ mice (black circles, solid line; * indicate signiﬁcance
levels of P < 0.05, Wilcoxon rank test). Rectal temperature was signiﬁcantly higher in Raldh1/ mice versus WT mice (Wilcoxon rank test; not
shown). (D) Insulin tolerance tests were performed onWT andRaldh1/mice as in (C) using standard approaches. These studies revealed a signiﬁcant
improvement in insulin sensitivity inRaldh1/mice (black circles, solid line) versusWTmice (open circles, dashed line; both tests performed after 16 h
fast). Data are presented as means ± S.E., *P < 0.05, Mann–Whitney test. Glucose tolerance tests revealed similar results (not shown).
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had similar systemic metabolic eﬀects as Rald, including sup-
pression of fat formation and improved insulin sensitivity as
seen with increased Rald levels [46]. Ultimately, the protection
against diet-induced obesity evident in Raldh1-deﬁcient mice
must be understood in terms of energy balance. Raldh1/mice
ate a similar amount of food and water as WT mice, suggesting
some other mechanism for their protection from obesity during
high fat feeding [37]. Metabolic cage studies revealed that
Raldh1/ mice had increased metabolic rates, with signiﬁcant
increases in basal body temperature (Fig. 2). These data identify
increased dissipation of energy, and a fundamental shift in en-
ergy balance in the presence of increased Rald concentrations.
Are these eﬀects speciﬁc to Raldh1 deﬁciency or are they evi-
dent in other models in which Rald levels are manipulated? In
ob/ob mice, administration of Rald, but not retinol or RA,
reproduced the phenotype seen with Raldh1 deﬁciency [37].
This divergence between administration of Rald and RA ar-
gues strongly that Rald exerts its own eﬀects that are distinct
from simply serving as a precursor for RA formation. Of note,administration of the general Raldh inhibitor citral to ob/ob
mice had similar eﬀects as seen with Raldh1 deﬁciency, includ-
ing inhibition of fat formation and improved insulin sensitivity
[37]. Further research will be required to more fully understand
the role of Rald in vivo and its speciﬁc mechanisms of action.
Such data will also help address whether Raldh1 inhibition
might be a therapeutic target for treating obesity and insulin
resistance. The prospect that Rald might serve as a potential
target for intervention would be bolstered by additional evi-
dence that Rald levels govern energy balance. Other studies
have begun to provide such support.
Other changes in retinoid production can shift energy balance.
Zhang and colleagues reported that mice deﬁcient in Rdh1man-
ifest obesity during feeding of a vitamin A-deﬁcient diet [47].
Rdh1 is a proximal enzyme in RA generation that catalyzes a
reversible oxidation of retinol to Rald. This reaction depends
on the substrate concentrations as well as the redox status of
the cell [1]. Rdh1 deﬁciency appears not to aﬀect RA production
in thesemice [47], further supporting a connectionbetweenobes-
ity and Rald metabolism. A deﬁciency in Bcm (or CMO1), an-
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Bcmutilizes another substrate, b-carotene, to generate twoRald
molecules [49]. In these animal studies [47,48], Rald concentra-
tion in fat and expression of Rald metabolizing enzymes in adi-
pose tissue did not directly examine the connection between
Rald and obesity but these ﬁndings are consistent with Rald
exerting inhibitory eﬀects on fat formation. This pathway is also
another example of crosstalk between PPAR and vitamin A
metabolism, since Bcm is a PPARc-regulated target gene [50].5. Apocarotenals: novel transcriptional modulators?
The evidence that certain retinoids may inhibit PPAR and
RXR responses and thus help regulate metabolism is not re-
stricted to Rald as a unique metabolite in the vitamin A path-
way. We identiﬁed that a separate pathway involved in
metabolizing b-carotene produces another aldehyde that can
also repress certain nuclear receptor responses, including those
of PPARc and PPARa [51]. It has long been recognized that
symmetric cleavage of b-carotene produces twoRaldmolecules,
which can be subsequently reduced to retinol or undergo oxida-
tion to form two RA molecules [49] (Fig. 3), thus explaining b-
carotene also being called provitamin A. More recent work
has established that b-carotene can also undergo asymmetric
cleavage, producing a series of molecules with varying chain
length known as apocarotenals (Fig. 3) [49]. Although apoca-
rotenals have been reported to exist in tissues, no functional role
for these molecules had previously been identiﬁed [52]. We pos-
tulated apocarotenals might also be involved in transcriptional
responses. We found that one speciﬁc apocarotenal, b-apo14 0-
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Fig. 4. Apo14, but not other related apocarotenals, inhibits PPARa responses in vitro and in vivo. (A) Apo14 promotes TNFa-mediated vascular
adhesion molecule-1 expression in vitro. Apo14 increased TNFa (20 ng/ml, 15 h) induced VCAM1 mRNA expression in human endothelial cells as
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time and order of stimulation. Apo14 prestimulation (10 lM) for 3 h, but not 15 min, reversed the known repression of TNFa-induced VCAM-1
mRNA expression in human endothelial cells seen with the PPARa agonist WY14643 (250 lM, 3 h). Using the same concentrations/conditions as
before, the opposite order of stimulation – WY ﬁrst followed by apo14 treatment – had no eﬀect on VCAM1 expression. Such data would suggest
possible competition between the PPARaWY and apo14 for PPARa activation. (B) The air pouch model is a well-established method for measuring
inﬂammatory cell recruitment to a subcutaneous air pouch generated in the dorsum of mice. In this model, apo14 increased leukocyte recruitment
in vivo in a PPARa-dependent manner. Pre-treatment with apo14 (10 lM, 2 h) increased TNFa-induced (25 ng/ml for 2 h) leukocyte recruitment
in vivo in WT mice (P < 0.001). In contrast, apo14 had no eﬀect in PPARa-deﬁcient mice. As seen in many other studies, PPARa deﬁciency is
associated with increased basal inﬂammation, as evident in the increased recruitment of inﬂammatory cells to the air pouch in the absence of PPARa.
O. Ziouzenkova, J. Plutzky / FEBS Letters 582 (2008) 32–38 37responses. The fact that the input for activating both RXR and
PPARs derive from the metabolism of dietary nutrients yield-
ing b-carotene metabolites, retinoids, and fatty acids identiﬁes
these receptors as potential links between diet, energy balance,
and pathologic conditions inﬂuenced by nutrition such as dia-
betes and atherosclerosis. Understanding how RXR and
PPARs are involved in such conditions, and how these recep-
tors might be best targeted for therapeutic beneﬁt, will require
considerably more studies. Two important but poorly under-
stood aspects of this RXR–PPAR network are now coming
under increased scrutiny, namely the coordinated interplay be-
tween RXR–PPAR signals and how natural mediators may
modulate RXR–PPAR responses. The concept of natural
PPAR and RXR inhibitors is relatively new [37,51] but adds
to the list of candidate mechanisms involved in helping termi-
nate if not regulate these important transcriptional mediators.
Other nuclear receptors have already established the relevance
of negative inputs to biologic responses. For example, the reg-
ulation of FXR, another RXR heterodimeric partner, occurs
in part through the production of speciﬁc, natural bile acids
with either agonistic and antagonistic properties [58,59]. Our
studies discussed here reveal that vitamin A and b-carotene
metabolism can produce transcriptionally active metabolites
with counteracting properties on speciﬁc nuclear receptors
and hence the metabolic pathways regulated by those receptors
[37,51]. Further insight into metabolism of vitamin A and its
bioactive metabolites will likely continue to reveal new targets
and mechanisms that will help explain how these pathways
control energy balance and might ultimately be manipulated
in the treatment of metabolic disorders.
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